Augmented demineralized bone matrix: a potential alternative for posterolateral lumbar spinal fusion.

Debdut Biswas, Jesse E. Bible, Peter H. Whang, Christopher P. Miller, Rebecca Jaw, Stephen Miller, Jonathan N. Grauer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Variable osteoinductive potential has been reported between and within production lots of different demineralized bone matrix (DBM) products. This study compared fusion rates of different manufactured lots and augmented formulations of DBM with a dose-response curve of recombinant human bone morphogenetic protein 2 (rhBMP-2) on inactivated DBM carrier in a posterolateral fusion rat model. Lumbar fusions were performed in 145 rats. In the control rats, we implanted autograft, graft alternative, including inactivated DBM, or nothing (ie, no graft). In the study rats, we implanted 1 of 2 BioSETR (RTI Biologics, Alachua, Florida) DBM lots, growth factor-enriched DBM, and inactivated DBM plus rhBMP-2 in different concentrations. Manual palpation revealed fusion rates of 25% (autograft), 0% (inactivated DBM), 17% (DBM donor A), and 36% (DBM donor B). The fusion rate of the most enhanced donor B graft (83%) was higher (P<.05) than that of autograft or unenhanced DBM. Inactivated DBM plus rhBMP-2 fused between 45% and 100%. There was no significant difference between DBM plus rhBPM-2 and the highest enrichment group of donor B. Differences between 2 DBM lots in an athymic rat ectopic bone formation model also were found in the spine fusion model. Enhanced DBM formulations were comparable with inactivated DBM plus rhBMP-2 with respect to performance and could represent a bone graft alternative in spine fusion.

Original languageEnglish (US)
Pages (from-to)531-538
Number of pages8
JournalAmerican journal of orthopedics (Belle Mead, N.J.)
Volume39
Issue number11
StatePublished - Nov 1 2010

Fingerprint

Spinal Fusion
Bone Matrix
Autografts
Transplants
Spine
Nude Rats
Palpation
Biological Products

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Biswas, Debdut ; Bible, Jesse E. ; Whang, Peter H. ; Miller, Christopher P. ; Jaw, Rebecca ; Miller, Stephen ; Grauer, Jonathan N. / Augmented demineralized bone matrix : a potential alternative for posterolateral lumbar spinal fusion. In: American journal of orthopedics (Belle Mead, N.J.). 2010 ; Vol. 39, No. 11. pp. 531-538.
@article{236b7314b85b42d8955513d2fce137bc,
title = "Augmented demineralized bone matrix: a potential alternative for posterolateral lumbar spinal fusion.",
abstract = "Variable osteoinductive potential has been reported between and within production lots of different demineralized bone matrix (DBM) products. This study compared fusion rates of different manufactured lots and augmented formulations of DBM with a dose-response curve of recombinant human bone morphogenetic protein 2 (rhBMP-2) on inactivated DBM carrier in a posterolateral fusion rat model. Lumbar fusions were performed in 145 rats. In the control rats, we implanted autograft, graft alternative, including inactivated DBM, or nothing (ie, no graft). In the study rats, we implanted 1 of 2 BioSETR (RTI Biologics, Alachua, Florida) DBM lots, growth factor-enriched DBM, and inactivated DBM plus rhBMP-2 in different concentrations. Manual palpation revealed fusion rates of 25{\%} (autograft), 0{\%} (inactivated DBM), 17{\%} (DBM donor A), and 36{\%} (DBM donor B). The fusion rate of the most enhanced donor B graft (83{\%}) was higher (P<.05) than that of autograft or unenhanced DBM. Inactivated DBM plus rhBMP-2 fused between 45{\%} and 100{\%}. There was no significant difference between DBM plus rhBPM-2 and the highest enrichment group of donor B. Differences between 2 DBM lots in an athymic rat ectopic bone formation model also were found in the spine fusion model. Enhanced DBM formulations were comparable with inactivated DBM plus rhBMP-2 with respect to performance and could represent a bone graft alternative in spine fusion.",
author = "Debdut Biswas and Bible, {Jesse E.} and Whang, {Peter H.} and Miller, {Christopher P.} and Rebecca Jaw and Stephen Miller and Grauer, {Jonathan N.}",
year = "2010",
month = "11",
day = "1",
language = "English (US)",
volume = "39",
pages = "531--538",
journal = "American Journal of Orthopedics",
issn = "1078-4519",
publisher = "Quadrant Healthcom Inc.",
number = "11",

}

Augmented demineralized bone matrix : a potential alternative for posterolateral lumbar spinal fusion. / Biswas, Debdut; Bible, Jesse E.; Whang, Peter H.; Miller, Christopher P.; Jaw, Rebecca; Miller, Stephen; Grauer, Jonathan N.

In: American journal of orthopedics (Belle Mead, N.J.), Vol. 39, No. 11, 01.11.2010, p. 531-538.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Augmented demineralized bone matrix

T2 - a potential alternative for posterolateral lumbar spinal fusion.

AU - Biswas, Debdut

AU - Bible, Jesse E.

AU - Whang, Peter H.

AU - Miller, Christopher P.

AU - Jaw, Rebecca

AU - Miller, Stephen

AU - Grauer, Jonathan N.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Variable osteoinductive potential has been reported between and within production lots of different demineralized bone matrix (DBM) products. This study compared fusion rates of different manufactured lots and augmented formulations of DBM with a dose-response curve of recombinant human bone morphogenetic protein 2 (rhBMP-2) on inactivated DBM carrier in a posterolateral fusion rat model. Lumbar fusions were performed in 145 rats. In the control rats, we implanted autograft, graft alternative, including inactivated DBM, or nothing (ie, no graft). In the study rats, we implanted 1 of 2 BioSETR (RTI Biologics, Alachua, Florida) DBM lots, growth factor-enriched DBM, and inactivated DBM plus rhBMP-2 in different concentrations. Manual palpation revealed fusion rates of 25% (autograft), 0% (inactivated DBM), 17% (DBM donor A), and 36% (DBM donor B). The fusion rate of the most enhanced donor B graft (83%) was higher (P<.05) than that of autograft or unenhanced DBM. Inactivated DBM plus rhBMP-2 fused between 45% and 100%. There was no significant difference between DBM plus rhBPM-2 and the highest enrichment group of donor B. Differences between 2 DBM lots in an athymic rat ectopic bone formation model also were found in the spine fusion model. Enhanced DBM formulations were comparable with inactivated DBM plus rhBMP-2 with respect to performance and could represent a bone graft alternative in spine fusion.

AB - Variable osteoinductive potential has been reported between and within production lots of different demineralized bone matrix (DBM) products. This study compared fusion rates of different manufactured lots and augmented formulations of DBM with a dose-response curve of recombinant human bone morphogenetic protein 2 (rhBMP-2) on inactivated DBM carrier in a posterolateral fusion rat model. Lumbar fusions were performed in 145 rats. In the control rats, we implanted autograft, graft alternative, including inactivated DBM, or nothing (ie, no graft). In the study rats, we implanted 1 of 2 BioSETR (RTI Biologics, Alachua, Florida) DBM lots, growth factor-enriched DBM, and inactivated DBM plus rhBMP-2 in different concentrations. Manual palpation revealed fusion rates of 25% (autograft), 0% (inactivated DBM), 17% (DBM donor A), and 36% (DBM donor B). The fusion rate of the most enhanced donor B graft (83%) was higher (P<.05) than that of autograft or unenhanced DBM. Inactivated DBM plus rhBMP-2 fused between 45% and 100%. There was no significant difference between DBM plus rhBPM-2 and the highest enrichment group of donor B. Differences between 2 DBM lots in an athymic rat ectopic bone formation model also were found in the spine fusion model. Enhanced DBM formulations were comparable with inactivated DBM plus rhBMP-2 with respect to performance and could represent a bone graft alternative in spine fusion.

UR - http://www.scopus.com/inward/record.url?scp=80053339745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053339745&partnerID=8YFLogxK

M3 - Article

C2 - 21623419

AN - SCOPUS:80053339745

VL - 39

SP - 531

EP - 538

JO - American Journal of Orthopedics

JF - American Journal of Orthopedics

SN - 1078-4519

IS - 11

ER -